Tirzepatide vs retatrutide vs mazdutide: receptors, trials, and comparison limits

Tirzepatide has large phase 3 randomized evidence and indication-specific regulatory decisions. Retatrutide has a prominent randomized phase 2 report and later-stage registered programs. Mazdutide has randomized early- and mid-stage reports in Chinese populations along with a jurisdiction-specific development path.

That maturity difference affects what can be concluded. A larger or later trial generally provides more information about a defined question, but it still does not answer a direct comparison unless the other molecule is included under the same protocol.

The frequently quoted weight-change values come from separate trials with different eligibility criteria, durations, groups, analysis estimands, missing-data strategies, behavioral support, and development objectives. Selecting the largest number ignores those design differences and can create a false league table.

A defensible cross-trial table should display population, diabetes inclusion or exclusion, duration, comparator, phase, primary endpoint, analysis set, adverse-event reporting, and status. It should label every efficacy contrast as indirect unless a randomized head-to-head study exists.

Useful comparative questions include durability, discontinuation, patient-relevant adverse events, cardiovascular and metabolic outcomes, performance in shared populations, and outcomes after treatment stops. Direct active-comparator trials or carefully conducted evidence synthesis would reduce uncertainty.

This page does not recommend a product or provide dose, titration, switching, combination, sourcing, or administration guidance. Regulatory status remains molecule-, product-, indication-, jurisdiction-, and date-specific.